Clinical Trials Logo

Clinical Trial Summary

This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including the response rate, the survival rate and the safety profile.


Clinical Trial Description

Patients with liver-only metastases colorectal cancer could potentially be cured following surgical resection of metastases. Recent evidence suggest that a triplet chemotherapy regimen, FOLFOXIRI has been associated with higher R0 resection. Eighty-nine eligible patients will be recruited at Cho Ray hospital in Vietnam. Patients will receive neoadjuvant FOLFOXIRI regimen every two weeks for up to 12 cycles and will undergo periodic imaging studies. The resectability of liver metastases will be assessed by a multidisciplinary team comprised of digestive surgeons, hepato-biliary surgeons, radiologists, and oncologists. This study will be helpful to establish a standard chemotherapy regimen for patients with liver-limited metastatic colorectal cancer. Moreover, this study will assess the surgical outcome, the response rate, the survival rate, the safety of triple drug chemotherapy and the association between conversion operable disease and various survival rate and patient's characteristics. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05362825
Study type Observational
Source Cho Ray Hospital
Contact Hao Dinh Thy Vuong, MD
Phone +84913122867
Email drthyhao@gmail.com
Status Recruiting
Phase
Start date February 18, 2022
Completion date January 23, 2025

See also
  Status Clinical Trial Phase
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT03562234 - The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
Recruiting NCT03732235 - TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Recruiting NCT06126419 - Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration N/A
Active, not recruiting NCT05616039 - I-FIGS Feasibility Study N/A
Withdrawn NCT05175092 - Living Donor Liver Transplantation for CRC Liver Metastases N/A
Recruiting NCT04798898 - Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation N/A
Not yet recruiting NCT06053996 - Hepatopulmonary Radio-sterilization With Immunotherapy N/A
Not yet recruiting NCT06071052 - TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens N/A
Recruiting NCT04491929 - Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Not yet recruiting NCT06050200 - TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery N/A
Enrolling by invitation NCT03444194 - Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study N/A
Not yet recruiting NCT05884723 - Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis N/A
Not yet recruiting NCT06185556 - COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases Phase 2/Phase 3
Recruiting NCT05755672 - On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
Recruiting NCT04595266 - Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Phase 2
Recruiting NCT04701281 - Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT06200831 - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases N/A
Active, not recruiting NCT04046445 - Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Phase 1